Antibody vectors for imaging.
暂无分享,去创建一个
Anna M Wu | A. Wu | Tove Olafsen | T. Olafsen
[1] A. Wu,et al. ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies). , 2010, Protein engineering, design & selection : PEDS.
[2] F. Salazar,et al. Recombinant Anti-CD20 Antibody Fragments for Small-Animal PET Imaging of B-Cell Lymphomas , 2009, Journal of Nuclear Medicine.
[3] J. Pagel,et al. Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primates. , 2009, Blood.
[4] Sanjiv S Gambhir,et al. Cys-diabody quantum dot conjugates (immunoQdots) for cancer marker detection. , 2009, Bioconjugate chemistry.
[5] L. Zardi,et al. Use of Uteroglobin for the Engineering of Polyvalent, Polyspecific Fusion Proteins* , 2009, The Journal of Biological Chemistry.
[6] Michaela Gebauer,et al. Engineered protein scaffolds as next-generation antibody therapeutics. , 2009, Current opinion in chemical biology.
[7] A. Wu,et al. MicroPET imaging of HER2+ tumors using F-18-labeled anti-HER2 diabody , 2009 .
[8] S. Ståhl,et al. Engineered affinity proteins for tumour‐targeting applications , 2009, Biotechnology and applied biochemistry.
[9] B. Oliva,et al. In Vivo Tumor Targeting and Imaging with Engineered Trivalent Antibody Fragments Containing Collagen-Derived Sequences , 2009, PloS one.
[10] G. Adams,et al. Affinity and avidity in antibody-based tumor targeting. , 2009, Cancer biotherapy & radiopharmaceuticals.
[11] C. R. Leemans,et al. 124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapy , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[12] Tara Heitner,et al. In Vivo Biodistribution, PET Imaging, and Tumor Accumulation of 86Y- and 111In-Antimindin/RG-1, Engineered Antibody Fragments in LNCaP Tumor–Bearing Nude Mice , 2009, Journal of Nuclear Medicine.
[13] Anna M. Wu,et al. Antibodies and Antimatter: The Resurgence of Immuno-PET , 2008, Journal of Nuclear Medicine.
[14] Shuming Nie,et al. Single chain epidermal growth factor receptor antibody conjugated nanoparticles for in vivo tumor targeting and imaging. , 2008, Small.
[15] A. Wu,et al. Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors. , 2008, Protein engineering, design & selection : PEDS.
[16] A. Wu,et al. Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2. , 2008, Bioconjugate chemistry.
[17] A. Wu,et al. Humanized Radioiodinated Minibody For Imaging of Prostate Stem Cell Antigen–Expressing Tumors , 2008, Clinical Cancer Research.
[18] Min-Yuan Chou,et al. The FASEB Journal • Research Communication Production of multivalent protein binders using a self-trimerizing collagen-like peptide scaffold , 2022 .
[19] S. Nuttall,et al. Display scaffolds: protein engineering for novel therapeutics. , 2008, Current opinion in pharmacology.
[20] J. Tait. Imaging of Apoptosis , 2008, Journal of Nuclear Medicine.
[21] A. Scott,et al. Tumor targeting by a multivalent single-chain Fv (scFv) anti-Lewis Y antibody construct. , 2008, Cancer biotherapy & radiopharmaceuticals.
[22] M. Rudin. Noninvasive imaging of receptor function: signal transduction pathways and physiological readouts. , 2008, Current opinion in drug discovery & development.
[23] Kevin C Weng,et al. Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. , 2008, Nano letters.
[24] S. Justesen,et al. Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues , 2008, The FEBS journal.
[25] K. Wittrup,et al. Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids , 2008, Molecular Cancer Therapeutics.
[26] Sun-Gu Lee,et al. Improving the productivity of single-chain Fv antibody against c-Met by rearranging the order of its variable domains. , 2008, Journal of microbiology and biotechnology.
[27] June-Key Chung,et al. Molecular-Genetic Imaging Based on Reporter Gene Expression , 2008, Journal of Nuclear Medicine.
[28] David A Mankoff,et al. Tumor Receptor Imaging , 2008, Journal of Nuclear Medicine.
[29] Weibo Cai,et al. Multimodality Molecular Imaging of Tumor Angiogenesis , 2008, Journal of Nuclear Medicine.
[30] W. Weber,et al. Tumor Cell Metabolism Imaging , 2008, Journal of Nuclear Medicine.
[31] Michael M. Schmidt,et al. Kinetics of anti-carcinoembryonic antigen antibody internalization: effects of affinity, bivalency, and stability , 2008, Cancer Immunology, Immunotherapy.
[32] G. Denardo,et al. Development of multivalent radioimmunonanoparticles for cancer imaging and therapy. , 2008, Cancer biotherapy & radiopharmaceuticals.
[33] C. Vanhove,et al. SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression , 2008, Molecular Imaging and Biology.
[34] J. Bading,et al. Biodistribution and tumor imaging of an anti-CEA single-chain antibody-albumin fusion protein. , 2008, Nuclear medicine and biology.
[35] C. Vanhove,et al. 99mTc-Labeled nanobodies: a new type of targeted probes for imaging antigen expression , 2008 .
[36] G. V. van Dongen,et al. Immuno-PET: a navigator in monoclonal antibody development and applications. , 2007, The oncologist.
[37] H. Bear,et al. Imaging multidrug resistance with 4-[18F]fluoropaclitaxel. , 2007, Nuclear medicine and biology.
[38] Y. Zhen,et al. Targeting TNF-α with a tetravalent mini-antibody TNF-TeAb , 2007 .
[39] M. Welch,et al. Small-Animal PET of Tumor Angiogenesis Using a 76Br-Labeled Human Recombinant Antibody Fragment to the ED-B Domain of Fibronectin , 2007, Journal of Nuclear Medicine.
[40] Sanjiv S. Gambhir,et al. Fusion of Gaussia Luciferase to an Engineered Anti-carcinoembryonic Antigen (CEA) Antibody for In Vivo Optical Imaging , 2007, Molecular Imaging and Biology.
[41] S. Morrison,et al. Targeting, Imaging, and Therapy Using a Humanized Antiprostate Stem Cell Antigen (PSCA) Antibody , 2007, Journal of immunotherapy.
[42] T. Stigbrand,et al. Tumor radioimmunolocalization in nude mice by mono- and divalent- single-chain Fv antiplacental alkaline phosphatase antibodies. , 2007, Cancer biotherapy & radiopharmaceuticals.
[43] S. Gambhir,et al. PET imaging of colorectal cancer in xenograft-bearing mice by use of an 18F-labeled T84.66 anti-carcinoembryonic antigen diabody. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[44] A. Wu,et al. Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy. , 2007, Cancer research.
[45] Jinwoo Cheon,et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging , 2007, Nature Medicine.
[46] Sanjiv S Gambhir,et al. Bifunctional antibody-Renilla luciferase fusion protein for in vivo optical detection of tumors. , 2006, Protein engineering, design & selection : PEDS.
[47] L. Dinkelborg,et al. Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[48] Alfred Buck,et al. Human monoclonal antibodies to domain C of tenascin-C selectively target solid tumors in vivo. , 2006, Protein engineering, design & selection : PEDS.
[49] J. Prieto,et al. Enhanced antiangiogenic therapy with antibody‐collagen XVIII NC1 domain fusion proteins engineered to exploit matrix remodeling events , 2006, International journal of cancer.
[50] J. Pagel,et al. Comparison of a tetravalent single-chain antibody-streptavidin fusion protein and an antibody-streptavidin chemical conjugate for pretargeted anti-CD20 radioimmunotherapy of B-cell lymphomas. , 2006, Blood.
[51] R. Weissleder,et al. In-vivo imaging of tumor associated urokinase-type plasminogen activator activity. , 2006, Journal of biomedical optics.
[52] J. Pagel,et al. A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies. , 2006, Cancer research.
[53] Jan E Schnitzer,et al. Screening phage display libraries for organ-specific vascular immunotargeting in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[54] L. Roque,et al. A multivalent recombinant antibody fragment specific for carcinoembryonic antigen , 2006, Biotechnology and applied biochemistry.
[55] S. Larson,et al. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[56] Anna M Wu,et al. Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.
[57] P. Hudson,et al. Engineered antibody fragments and the rise of single domains , 2005, Nature Biotechnology.
[58] I. Pastan,et al. Pretargeted radioimmunotherapy of mesothelin-expressing cancer using a tetravalent single-chain Fv-streptavidin fusion protein. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[59] S. Gambhir,et al. Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging. , 2005, Cancer research.
[60] He Wang,et al. [Study on p53 tetramerization domain in improving functional affinity and biological activity of antibody]. , 2005, Zhonghua yi xue za zhi.
[61] Mohan Doss,et al. Quantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. , 2005, Cancer research.
[62] Sanjiv S Gambhir,et al. Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments. , 2005, Cancer research.
[63] A. Corti,et al. The three-step pretargeting approach reduces the human anti-mouse antibody response in patients submitted to radioimmunoscintigraphy and radioimmunotherapy , 1997, European Journal of Nuclear Medicine.
[64] M. Sliwkowski,et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. , 2004, Molecular biology of the cell.
[65] M. Brechbiel,et al. A Single Treatment of Yttrium-90-labeled CHX-A″–C6.5 Diabody Inhibits the Growth of Established Human Tumor Xenografts in Immunodeficient Mice , 2004, Cancer Research.
[66] L. Adler,et al. Quantitation of small-animal (124)I activity distributions using a clinical PET/CT scanner. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[67] Joost Bart,et al. PET Studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. , 2004, Current pharmaceutical design.
[68] Jinha M. Park,et al. Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting. , 2004, Protein engineering, design & selection : PEDS.
[69] S. Gambhir,et al. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. , 2004, Protein engineering, design & selection : PEDS.
[70] Sanjiv S Gambhir,et al. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[71] D. Filpula,et al. Tailoring structure-function and pharmacokinetic properties of single-chain Fv proteins by site-specific PEGylation. , 2003, Protein engineering.
[72] D. Lauffenburger,et al. Quantitative Analysis of HER2-mediated Effects on HER2 and Epidermal Growth Factor Receptor Endocytosis , 2003, Journal of Biological Chemistry.
[73] M. Alyanakian,et al. Pharmacokinetics of total immunoglobulin G and immunoglobulin G subclasses in patients undergoing replacement therapy for primary immunodeficiency syndromes , 2003, Vox sanguinis.
[74] Christilyn P. Graff,et al. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. , 2003, Cancer research.
[75] S. Gambhir,et al. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. , 2003, Genes & development.
[76] L. Zardi,et al. Selective targeting of tumoral vasculature: Comparison of different formats of an antibody (L19) to the ED‐B domain of fibronectin , 2002, International journal of cancer.
[77] R. Weissleder,et al. In vivo imaging of gene delivery and expression , 2002 .
[78] S. Batra,et al. 99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[79] G. Adams,et al. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. , 2001, Cancer research.
[80] R. Reilly,et al. Rapid imaging of human melanoma xenografts using an scFv fragment of the human monoclonal antibody H11 labelled with 111In , 2001, Nuclear medicine communications.
[81] A. Plückthun,et al. Tumor Targeting of Mono-, Di-, and Tetravalent Anti-p185HER-2 Miniantibodies Multimerized by Self-associating Peptides* , 2001, The Journal of Biological Chemistry.
[82] J. Wong,et al. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. , 2001, Bioconjugate chemistry.
[83] H R Hoogenboom,et al. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. , 2001, Journal of immunological methods.
[84] S. Batra,et al. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. , 2000, Cancer research.
[85] U. Nielsen,et al. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. , 2000, Cancer research.
[86] H. Mantsch,et al. Noninvasive localization of tumors by immunofluorescence imaging using a single chain Fv fragment of a human monoclonal antibody with broad cancer specificity , 2000, Cancer.
[87] A. Kortt,et al. ScFv multimers of the anti-neuraminidase antibody NC10: shortening of the linker in single-chain Fv fragment assembled in V(L) to V(H) orientation drives the formation of dimers, trimers, tetramers and higher molecular mass multimers. , 2000, Protein engineering.
[88] S S Gambhir,et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[89] C. Halin,et al. Infrared photodetection for the in vivo localisation of phage-derived antibodies directed against angiogenic markers. , 1999, Journal of immunological methods.
[90] Andreas Plückthun,et al. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)–carbonyl complex , 1999, Nature Biotechnology.
[91] V. Erdmann,et al. Cell-free expression of two single-chain monoclonal antibodies against lysozyme: effect of domain arrangement on the expression. , 1999, Journal of biochemistry.
[92] R L Wahl,et al. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. , 1999, Radiographics : a review publication of the Radiological Society of North America, Inc.
[93] S. Morrison,et al. Chimeric human-mouse IgG antibodies with shuffled constant region exons demonstrate that multiple domains contribute to in vivo half-life. , 1998, Cancer research.
[94] G. Adams,et al. Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. , 1998, British Journal of Cancer.
[95] David K. Stevenson,et al. Bioluminescent indicators in living mammals , 1998, Nature Medicine.
[96] G. Adams,et al. Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies. , 1998, Cancer research.
[97] K A Chester,et al. Preclinical characterization and in vivo imaging studies of an engineered recombinant technetium-99m-labeled metallothionein-containing anti-carcinoembryonic antigen single-chain antibody. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[98] D. Klatzmann,et al. A recombinant human scFv anti-Rh(D) antibody with multiple valences using a C-terminal fragment of C4-binding protein. , 1997, Blood.
[99] A. Plückthun,et al. New protein engineering approaches to multivalent and bispecific antibody fragments. , 1997, Immunotechnology : an international journal of immunological engineering.
[100] G. Adams,et al. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. , 1996, Journal of molecular biology.
[101] A. Plückthun,et al. Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen. , 1996, Journal of immunology.
[102] L E Williams,et al. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. , 1996, Cancer research.
[103] K. Chester,et al. Technetium-99m radiolabeling using a phage-derived single-chain Fv with a C-terminal cysteine. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[104] L E Williams,et al. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. , 1996, Immunotechnology : an international journal of immunological engineering.
[105] J. Huston,et al. Enhanced tumor specificity of 741F8-1 (sFv')2, an anti-c-erbB-2 single-chain Fv dimer, mediated by stable radioiodine conjugation. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[106] I. Pastan,et al. Biodistribution of 18F- and 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2 alpha receptor-positive tumor xenografts. , 1995, Cancer research.
[107] L L Houston,et al. Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[108] M. Little,et al. Bifunctional and multimeric complexes of streptavidin fused to single chain antibodies (scFv). , 1995, Journal of immunological methods.
[109] R. Owens,et al. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. , 1994, Cancer research.
[110] A. Lawson,et al. Multimerization behaviour of single chain Fv variants for the tumour-binding antibody B72.3. , 1994, Protein engineering.
[111] A. Chu,et al. Genetically engineered antibodies for diagnostic pathology. , 1994, Human pathology.
[112] K. D. Hardman,et al. An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. , 1993, Protein engineering.
[113] L L Houston,et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. , 1993, Cancer research.
[114] T Prospero,et al. "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[115] H. Oppermann,et al. Rapid infarct imaging with a technetium-99m-labeled antimyosin recombinant single-chain Fv: evaluation in a canine model of acute myocardial infarction. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[116] T. Yokota,et al. Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules. , 1992, Cancer research.
[117] A. Plückthun,et al. Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. , 1992, Biochemistry.
[118] T. Yokota,et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. , 1991, Cancer research.
[119] K. Fujimori,et al. Barrier ' ' Microscopic Tumor Nodules : Consequences of a ' ' Binding Site An Analysis of Monoclonal Antibody Distribution in Updated , 2006 .
[120] K. D. Hardman,et al. In vivo tumor targeting of a recombinant single-chain antigen-binding protein. , 1990, Journal of the National Cancer Institute.
[121] K. D. Hardman,et al. Single-chain antigen-binding proteins. , 1988, Science.
[122] R. Bruccoleri,et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[123] B. Kudryk,et al. Thrombus imaging with indium-111 and iodine-131-labeled fibrin-specific monoclonal antibody and its F(ab')2 and Fab fragments. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[124] D. Carlo,et al. Clinical parameters related to optimal tumor localization of indium-111-labeled mouse antimelanoma monoclonal antibody ZME-018. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.